ClinicalTrials.gg
RecruitingNCT03747133Updated Jun 4, 2026

SABR for Renal Tumors

An interventional study of Stereotactic Ablative Radiotherapy in Renal Tumor, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2018; still recruiting 8 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Carcinoma, Renal Cell by University Health Network, Toronto — 1 open to participants now, 1 under way, none of them phase 3. Carcinoma, Renal Cell · University Health Network, Toronto.

Started
2018
the only one that year
No phase
3 of 11
1 open now
Registered
9th of 11
by date

Among the 11 studies in Carcinoma, Renal Cell by University Health Network, Toronto, this one is the only one that started in 2018, is one of 3 with no phase, and was the 9th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

1 of the 11 studies in Carcinoma, Renal Cell by University Health Network, Toronto is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Carcinoma, Renal Cell by University Health Network, Toronto, or all of them as a file.
02

Study summary

Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. The usual treatment for this type of cancer is surgery. Considering the most common patients are an average age of 65 and some are not suitable candiates for surgery, there is great interest in non-surgical alternatives for kidney cancer treatments. This study will investigate the use of Stereotactic Ablative Radiosurgery (SABR) for renal tumors. SABR is a non-invasive alternative, which involves delivery of high doses of radiation to the target, while minimizing the risk of injury to the surrounding organs. Patients will be seen before and end of treatmetn and will be followed at 4 month intervals for up to 2 years. During the follow ups, patients will be asked to complete a quality of life questionnaire and will have standard of care imaging.

03

Conditions studied

  • Renal Tumor

Keywords

  • Stereotactic Body Radiation Therapy
  • SABR
  • Radiation Therapy
  • Renal Cell Carcinoma
  • RCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Solid Kidney Mass (primary RCC or ) amenable to SABR ≤6cm
  • Histological or radiological diagnosis of renal tumor
  • Inoperable: High risk for surgery or declined surgery
  • performance status of 0-3

Exclusion criteria

Exclusion Criteria:

  • ≥5 active
  • Systemic therapy (except endocrine therapy) within 60 days prior to SABR
  • Prior abdominal radiotherapy with fields overlap resulting in excessive doses to the involved kidney
  • Patients with end stage renal failure > 4(KDOQI guidelines)
  • Familial Syndrome: Von Hippel-Lindau disease, Polycystic Kidney Disease, Hereditary Papillary RCC or Tuber Sclerosis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Stereotactic Ablative Radiotherapy

    Adult patients with Kidney mass (either primary or metastasis) amenable to SABR

    Radiation: Stereotactic Ablative Radiotherapy

Interventions

  • RadiationStereotactic Ablative Radiotherapy

    Stereotactic Ablative Radiotherapy to renal tumors with a dose of 27.5-40 Gy in 5 fractions.

06

What researchers measure

Primary outcomes

  1. To evaluate the radiation induced renal impairments in patients receiving SABR.

    The prevalence of nephron toxicity in patients treated with SABR, measured by the change in Glomerular Filtration Rate (GFR) every 4 months over 2 years.

    Time frame: 2 years

Secondary outcomes

  1. Chronic Kidney Disease Stage Progression

    Chronic kidney disease stage progression after SABR, assessed by the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines

    Time frame: 2 years

  2. 2-year Local recurrence rate

    2 year local recurrence rate of kidney tumors treated with SABR, measured by assessing the change of irradiated kidney function on functional imaging.

    Time frame: 2 years

  3. Patient Reported Outcomes

    The change in quality of life of patients treated with SABR, assessed through the use of NCCN FKSI-19 questionnaire.

    Time frame: 2 years

  4. Incidence of acute and late toxicities

    The incidence of acute (≤3 months) and late complication of interest (GI or GU complications, high blood pressure and adrenal insufficiency) as assessed by CTCAE version 5.0.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • University Health Network - Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • Andrew McPartlin, MD · Contactandrew.mcpartlin@rmp.uhn.ca · 416-946-4501
    • Andrew McPartlin, MD · Principal investigator
    • Andrew Bayley, MD · Sub investigator
08

References and documents

Publications

  • Glicksman RM, Winter J, McPartlin A, Santiago AT, Wang K, Bernstein J, Dang J, Tsui G, Chung P, Mesci A, Gutierrez Valencia E, Raman S, Berlin A, Catton C, Bayley A, Warde P, Krishna S, Finelli A, Hamilton RJ, Pace KT, Kitchlu A, Helou J. Stereotactic Body Radiation Therapy for Renal Tumors: A Prospective Phase 2 Clinical Trial. Int J Radiat Oncol Biol Phys. 2026 May 1;125(1):154-163. doi: 10.1016/j.ijrobp.2025.11.005. Epub 2025 Nov 23. PubMed 41290048 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2018 (actual). Primary completion is estimated for Nov 2027, 108 months after the start.

Of 120 non-industry interventional studies with no phase under Carcinoma, Renal Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 114. This study's planned 108 months is above that.

Counting every sponsor, half of 127 studies reached it within 45 months; a quarter within 21 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2018
First posted
Nov 20, 2018
StartActual
Nov 1, 2018
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03747133
Responsible party
Sponsor
First posted
Nov 20, 2018
Start date
Nov 1, 2018
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Jun 4, 2026

Study contacts

Rachel Glicksman, MD
Contact
rachel.glicksman@uhn.ca
416-946-4501 ext. 4483
Rachel Glicksman, MD
principal investigator · The Princess Margaret Cancer Foundation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion